Martins, A.Oliveira, D. SantosMartins, F. R.Nicolau, R.Pinheiro, F. OliveiraRato, M.Bernardo, A.Pimenta, S.Bernardes, M.Costa, L.2025-03-142025-03-142023-060003-4967http://hdl.handle.net/10400.1/26909European Congress of Rheumatology (EULAR)Biological disease-modifying antirheumatic drugs (bDMARDs) have revolutionized the treatment of chronic inflammatory rheumatic diseases. However, the physician and the patient should be aware of possible adverse reactions. Skin is one of the most frequent organs involved in bDMARD adverse reactions and immune-mediated skin lesions (IMSL) have rarely been described before in cohort studies and their incidence is unknown.engbDMARDSkinconference object10.1136/annrheumdis-2023-eular.2044